Zelluna ASA Celebrates Positive Growth in Q1 2025 Performance

Zelluna ASA Reports First Quarter 2025 Financial Results

Zelluna ASA, a pioneer in developing innovative allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, has announced its financial results for the first quarter of the year. The company aims to provide groundbreaking treatments that could potentially change the lives of patients confronting cancer.

First Quarter Highlights

The first quarter of 2025 has been marked by remarkable milestones for Zelluna ASA. A significant achievement occurred on March 3, 2025, when the company completed a strategic merger with Ultimovacs ASA and Zelluna Immunotherapy AS. This merger was coupled with a private placement that raised gross proceeds of MNOK 51.7, all while making sure the conditions for a successful integration were fulfilled.

This successful combination marks Zelluna’s strong positioning within the biotechnology sector. Following the merger, Zelluna underwent a name change and ticker code adjustment, transitioning from Ultimovacs ASA to Zelluna ASA with the ticker 'ZLNA', reflecting its new direction.

Advancements in TCR-NK Cell Therapies

Manufacturing Breakthrough

On April 22, 2025, Zelluna reported a significant leap forward in scaling and automating its proprietary manufacturing process for TCR-NK cell therapies. This advancement is not only vital for the company's clinical entry but also assures that the innovative treatments will be accessible to patients in need.

The new manufacturing process is versatile and can accommodate various products from the Zelluna pipeline, thereby enhancing efficiency and further solidifying the company's standing within the TCR-NK therapeutic domain. By allowing hundreds of doses to be produced from a single batch, this method signifies outstanding scalability and a promising reduction in costs.

Financial Overview

The financial report reveals total operating expenses amounting to MNOK 22.2 for Q1 2025. Moreover, the company faced a net negative cash flow from operational activities, registering MNOK 36.0 during the quarter. Notably, proceeds from equity issuance reached MNOK 51.7, and net cash acquired from the business combination stood at MNOK 92.3. This culminated in a net increase in cash and equivalents of MNOK 108.0 for the first quarter, bringing the total cash and cash equivalents to MNOK 135.3 by the end of March.

Additionally, a reverse share split was executed on March 31, 2025, resulting in a new outstanding share count of 20,227,066, reflecting a consolidation where ten shares became one.

Looking Ahead

As the company prepares to publish its detailed quarterly report and presentation, anticipated for May 8, 2025, stakeholders are encouraged to remain engaged. A conference call will also be held on the same day, allowing investors and interested parties to ask questions and learn more about Zelluna’s trajectory.

Investing in Zelluna ASA represents a commitment to pioneering cancer treatments that possess the potential to change patient lives. With a team rich in biotechnological experience and a clear vision for the future, Zelluna is set to make a lasting impact.

Contact Information

For more inquiries, please reach out to:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632

About Zelluna ASA

Zelluna’s mission is to provide transformative treatments capable of curing advanced solid cancers while ensuring safety and costs are managed effectively. The company focuses on harnessing the immune system's power to develop sophisticated, “off the shelf” TCR-NK therapies that can revolutionize cancer treatment.

To learn more about Zelluna ASA and their products, please visit www.zelluna.com.

Frequently Asked Questions

What is Zelluna ASA's main focus in biotechnology?

Zelluna ASA primarily focuses on developing T Cell Receptor based Natural Killer (TCR-NK) therapies for cancer treatment, aiming for safe and effective cures.

How did Zelluna perform financially in Q1 2025?

The company reported total operating expenses of MNOK 22.2, with a cash flow increase resulting from the successful equity raise of MNOK 51.7.

What significant merger did Zelluna complete recently?

Zelluna completed a merger with Ultimovacs ASA and Zelluna Immunotherapy AS, which facilitated a transition to the new company structure.

What are the expected benefits of Zelluna's new manufacturing process?

The new manufacturing process is designed to enhance scalability, enabling the production of hundreds of doses at a lower cost, making treatments more accessible.

How can interested parties ask questions about Zelluna's performance?

Zelluna will host a conference call on May 8, 2025, allowing for direct inquiries and discussions regarding their performance and future prospects.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.